Blueprint Medicines (BPMC) PT Raised to $147 at Goldman Sachs, Following Earnings

July 29, 2021 2:04 PM EDT
Get Alerts BPMC Hot Sheet
Price: $105.18 -0.77%

Rating Summary:
    13 Buy, 6 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 15 | Down: 9 | New: 24
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Goldman Sachs analyst Salveen Richter raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $147.00 (from $144.00) while maintaining a Buy rating.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change

Related Entities

Goldman Sachs, Earnings